Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics Inc (DE:PGF)
:PGF
Total Valuation
Protagonist Therapeutics has a market cap or net worth of €4.29B. The enterprise value is ―.
Market Cap€4.29B
Enterprise Value―
Share Statistics
Protagonist Therapeutics has 62,211,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,211,320
Owned by Insiders1.63%
Owned by Institutions0.42%
Financial Efficiency
Protagonist Therapeutics’s return on equity (ROE) is 0.41 and return on invested capital (ROIC) is 35.69%.
Return on Equity (ROE)0.41
Return on Assets (ROA)0.37
Return on Invested Capital (ROIC)35.69%
Return on Capital Employed (ROCE)0.36
Revenue Per Employee3.50M
Profits Per Employee2.22M
Employee Count124
Asset Turnover0.58
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protagonist Therapeutics is ―. Protagonist Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio5.47
PB Ratio3.52
Price to Fair Value3.52
Price to FCF13.00
Price to Operating Cash Flow77.48
PEG Ratio-0.02
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.
Revenue434.43M
Gross Profit434.43M
Operating Income252.84M
Pretax Income279.41M
Net Income275.19M
EBITDA253.67M
Earnings Per Share (EPS)4.47
Cash Flow
In the last 12 months, operating cash flow was 65.47M and capital expenditures -1.76M, giving a free cash flow of 63.71M billion.
Operating Cash Flow65.47M
Free Cash Flow63.71M
Free Cash Flow per Share1.02
Dividends & Yields
Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change56.39%
50-Day Moving Average58.32
200-Day Moving Average47.04
Relative Strength Index (RSI)66.51
Average Volume (3m)10.00
Important Dates
Protagonist Therapeutics upcoming earnings date is Mar 18, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
Protagonist Therapeutics as a current ratio of 12.48, with Debt / Equity ratio of 1.67%
Current Ratio12.48
Quick Ratio12.48
Debt to Market Cap0.00
Net Debt to EBITDA-0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protagonist Therapeutics has paid 4.22M in taxes.
Income Tax4.22M
Effective Tax Rate0.02
Enterprise Valuation
Protagonist Therapeutics EV to EBITDA ratio is 9.06, with an EV/FCF ratio of 12.53.
EV to Sales5.27
EV to EBITDA9.06
EV to Free Cash Flow12.53
EV to Operating Cash Flow12.44
Balance Sheet
Protagonist Therapeutics has €576.12M in cash and marketable securities with €10.75M in debt, giving a net cash position of €565.37M billion.
Cash & Marketable Securities€576.12M
Total Debt€10.75M
Net Cash€565.37M
Net Cash Per Share€9.09
Tangible Book Value Per Share€10.97
Margins
Gross margin is 99.70%, with operating margin of 58.20%, and net profit margin of 63.34%.
Gross Margin99.70%
Operating Margin58.20%
Pretax Margin64.32%
Net Profit Margin63.34%
EBITDA Margin58.20%
EBIT Margin58.20%
Analyst Forecast
The average price target for Protagonist Therapeutics is €76.93, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€76.93
Price Target Upside12.30% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast―